Fulcrum Therapeutics (FULC) CFO receives 170,000 stock options at $10.72 strike

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Fulcrum Therapeutics reported an equity award to its Chief Financial Officer, Alan Musso. On February 2, 2026, he received a stock option to purchase 170,000 shares of common stock at an exercise price of $10.72 per share. Following this grant, he beneficially owns 170,000 derivative securities tied to company stock.

The option is scheduled to vest in equal quarterly installments over four years, beginning on January 1, 2026, and each vesting date requires his continued service. This type of award aligns the CFO’s potential compensation with future stock performance over a multi‑year period.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Musso Alan A

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	170,000	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 170,000 shares (Direct)

Footnotes (1)

[object Object]

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 02/04/2026 - 04:10 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Musso Alan A

(Last)

(First)

(Middle)

C/O FULCRUM THERAPEUTICS, INC.

26 LANDSDOWNE STREET

(Street)

CAMBRIDGE

02139

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Fulcrum Therapeutics, Inc. [ FULC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (right to buy)	$10.72	02/02/2026		A		170,000		⁽¹⁾	02/01/2036	Common Stock	170,000	$0.00	170,000	D

Explanation of Responses:

1. This option was granted on February 2, 2026 and is scheduled to vest in equal quarterly installments over four years beginning on the vesting commencement date of January 1, 2026, subject to the reporting person's continued service on each such vesting date.

	/s/ Alan Musso	02/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Fulcrum Therapeutics (FULC) report for its CFO?

Fulcrum Therapeutics reported a stock option grant to CFO Alan Musso. He received options for 170,000 shares of common stock, creating a multi-year equity incentive tied to the company’s future stock performance.

How many Fulcrum Therapeutics (FULC) options were granted to the CFO?

The CFO received stock options covering 170,000 shares of Fulcrum Therapeutics common stock. This entire amount is reported as beneficially owned derivative securities following the transaction, subject to the vesting schedule and continued service conditions.

What is the exercise price of the Fulcrum Therapeutics (FULC) CFO stock options?

The reported stock options have an exercise price of $10.72 per share. This means the CFO can buy Fulcrum Therapeutics common stock at $10.72 when options vest and are exercised, regardless of the then-current market price.

How do the Fulcrum Therapeutics (FULC) CFO options vest over time?

The options vest in equal quarterly installments over four years. Vesting begins on January 1, 2026, and each quarterly tranche requires the CFO’s continued service on the applicable vesting date to become exercisable.

Is the Fulcrum Therapeutics (FULC) CFO option grant classified as a direct holding?

Yes, the Form 4 classifies the 170,000 stock options as directly owned. The ownership form is reported as “D” for direct, and no footnote indicates that the options are held through another entity or with restricted authority.

What type of security was granted to the Fulcrum Therapeutics (FULC) CFO?

The grant consists of a stock option, described as a “Stock Option (right to buy).” Each option, once vested and exercised, entitles the CFO to purchase one share of Fulcrum Therapeutics common stock at the fixed exercise price.